Drug combination study reveals new clues to treatment resistance in deadly melanoma
Uveal melanoma is a rare, aggressive cancer that starts inside the eye and often spreads to the liver. Few treatment options exist, and unlike some forms of skin melanoma that can respond well to modern therapies, metastatic uveal melanoma (MUM) remains difficult to treat.
A trial examining the combination of defactinib and avutometinib in 12 patients with metastatic uveal melanoma yielded no tumor shrinkage after two cycles. Six patients experienced stable disease while six saw disease progression. The study, published in Cancers, utilized synthetic lethality analysis to predict the potential effectiveness of this drug combination.
After analyzing tumor samples before and after treatment, researchers noticed that higher levels of ALDH1A3, an enzyme linked to treatment resistance, were present in progressing tumors, while stable tumors had lower levels of this enzyme. Additionally, tumors that progressed maintained biochemical signals supporting cancer cell survival.
These findings indicate possible resistance markers and could guide researchers in developing more effective therapies. Despite the disappointing outcome, the study underscores the importance of translating laboratory discoveries into clinical trials and using results to further scientific progress.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
